Generate Biomedicines, Inc. (GENB)
NASDAQ:GENB
Want to see GENB full AI Analyst Report?
GENB Stock Chart & Stats
$12.45
--
Market closed
$12.45
--
Day’s Range― - ―
52-Week Range$11.00 - $16.75
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
$1.71B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.89
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding128,192,490
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$25.40Price Target Upside104.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained top-line growth demonstrates early commercial traction and validates the platform's ability to generate paying programs or partnerships. Over 2-6 months this trend supports continued investment in R&D and provides a foundation for scaling revenue and improving operating leverage if maintained.
AI-driven Discovery PlatformA machine-learning protein design platform is a durable competitive asset: it can produce repeatable, scalable discovery across multiple disease areas, shorten timelines, and enable partnership/licensing revenue. Platform-led R&D offers structural advantages versus single-product biotechs.
High Reported Gross MarginReported 100% gross margin suggests very low direct COGS and platform-like economics for revenue today. If commercialized, this structural margin profile supports strong operating leverage and the potential for durable margin expansion as SG&A and R&D scale more efficiently.
Bears Say
Widening Net LossesMaterial and growing net losses reflect high ongoing R&D and operating expenditures that outpace revenues. Persisting large deficits erode financial flexibility, increase reliance on external funding, and can delay path to self-sustaining operations absent meaningful revenue scale or partnering milestones.
Accelerating Cash BurnCash outflows closely track net losses, indicating losses translate into real funding needs. Rapid negative operating and free cash flow create durable refinancing risk over months, forcing dilutive raises or debt, which can constrain strategic choices and slow program advancement.
Deeply Negative EquityA substantially negative equity position and shrinking assets weaken the balance sheet, limiting traditional financing options and increasing solvency and covenant risks. This structural weakness hinders long-term flexibility and elevates the probability of dilutive or costly capital solutions.
GENB FAQ
What was Generate Biomedicines, Inc.’s price range in the past 12 months?
Generate Biomedicines, Inc. lowest stock price was $11.00 and its highest was $16.75 in the past 12 months.
What is Generate Biomedicines, Inc.’s market cap?
Generate Biomedicines, Inc.’s market cap is $1.71B.
When is Generate Biomedicines, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Generate Biomedicines, Inc.’s earnings last quarter?
Currently, no data Available
Is Generate Biomedicines, Inc. overvalued?
According to Wall Street analysts Generate Biomedicines, Inc.’s price is currently Undervalued.
Does Generate Biomedicines, Inc. pay dividends?
Generate Biomedicines, Inc. does not currently pay dividends.
What is Generate Biomedicines, Inc.’s EPS estimate?
Generate Biomedicines, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Generate Biomedicines, Inc. have?
Generate Biomedicines, Inc. has 128,192,490 shares outstanding.
What happened to Generate Biomedicines, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Generate Biomedicines, Inc.?
Currently, no hedge funds are holding shares in GENB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Generate Biomedicines, Inc. Stock Smart Score
Company Description
Generate Biomedicines, Inc.
Generate Biomedicines, Inc. is a U.S.-based company pioneering generative biology, leveraging machine learning for the discovery and advancement of novel protein therapeutics. Their core approach involves developing drugs using protein-based modalities. The company's pipeline includes several key candidates: GB-0895, an investigational long-acting anti-TSLP monoclonal antibody designed for bi-annual dosing in severe asthma; GB-4362, an MMAE payload neutralizer monoclonal antibody; and GB-5267, a MUC16 CAR-T cell therapy. Integral to their work is the Generate Platform, a sophisticated system engineered to be versatile across diverse therapeutic areas and protein modalities. This platform combines computational innovation with scalable biohardware, allowing them to tackle therapeutic hurdles beyond the capabilities of traditional technologies. Established in 2018, the company was initially known as Generate Biologics, Inc. before rebranding to Generate Biomedicines, Inc. in February 2020. Its headquarters are located in Somerville, Massachusetts.
GENB Stock 12 Month Forecast
Average Price Target
$25.40
▲(104.02% Upside)
Ownership Overview
52.07% Insiders
5.30% Other Institutional Investors
42.11% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---